Immunomodulatory agents for prophylaxis and therapy of infections (Q33895630)

29 July 2017

1 reference

title

Immunomodulatory agents for prophylaxis and therapy of infections (English)

1 reference

29 July 2017

Masihi KN

1

1 reference

29 July 2017

1 April 2000

1 reference

International Journal of Antimicrobial Agents

29 July 2017

1 reference

29 July 2017

14

1 reference

29 July 2017

3

1 reference

29 July 2017

181-191

1 reference

Trends in infectious diseases mortality in the United States

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Consequences of bacterial resistance to antibiotics in medical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Antibacterial agents--phagocytes: new concepts for old in immunomodulation

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guérin strains that secrete cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Effectiveness of thymostimulin and study of lymphocyte-dependent antibacterial activity in children with recurrent respiratory infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Safety and efficacy of thymopentin in zidovudine (AZT)-treated asymptomatic HIV-infected subjects with 200-500 CD4 cells/mm3: a double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Combination treatment with zidovudine, thymosin alpha 1 and interferon-alpha in human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Efficacy of combination therapy with amantadine, thymosin alpha 1 and alpha/beta interferon in mice infected with influenza A virus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Prospectives on the treatment of chronic hepatitis B and chronic hepatitis C with thymic peptides and antiviral agents

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Methyl inosine monophosphate: a potential immunotherapeutic for early human immunodeficiency virus (HIV) infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Inosine pranobex in the treatment of HIV infection: A review

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Potentiation of host defense mechanism against infection by a cytokine inducer, an acyl-MDP derivative, MDP-Lys(L18) (romurtide) in mice and humans

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

MDP derivatives and resistance to bacterial infections in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Muramyl dipeptide inhibits replication of human immunodeficiency virus in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Role of curdlan sulfate in the binding of HIV-1 gp120 to CD4 molecules and the production of gp120-mediated TNF-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Down-regulation of tumor necrosis factor-alpha, moderate reduction of interleukin-1beta, but not interleukin-6 or interleukin-10, by glucan immunomodulators curdlan sulfate and lentinan.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Prevention by gamma interferon of fatal infection with Listeria monocytogenes in mice treated with cyclosporin A

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Growth of Listeria monocytogenes in murine macrophages and its modulation by cytokines; activation of bactericidal activity by interleukin-4 and interleukin-6

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

In vivo modulation of the murine immune response to Francisella tularensis LVS by administration of anticytokine antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Role of gamma interferon in Toxoplasma gondii infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Reduction in intensity of Pneumocystis carinii pneumonia in mice by aerosol administration of gamma interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Protective role of gamma interferon in experimental pulmonary paracoccidioidomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Antiviral effects of recombinant tumour necrosis factor in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Respiratory syncytial virus replication in human lung epithelial cells: inhibition by tumor necrosis factor alpha and interferon beta

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Effects of TNF in bacterial infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) or tumour necrosis factor-alpha (TNF-alpha) activate human alveolar macrophages to inhibit growth of Mycobacterium avium complex

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Recombinant human granulocyte colony-stimulating factor and Pseudomonas burn wound sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Recombinant murine granulocyte colony-stimulating factor protects against acute disseminated Candida albicans infection in nonneutropenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Effect of granulocyte colony-stimulating factor (G-CSF) in human immunodeficiency virus-infected patients: increase in numbers of naive CD4 cells and CD34 cells makes G-CSF a candidate for use in gene therapy or to support antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Immunomodulatory treatment of Mycobacterium avium complex bacteremia in patients with AIDS by use of recombinant granulocyte-macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Enhanced resistance against Listeria monocytogenes achieved by pretreatment with granulocyte colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Granulocyte-macrophage colony-stimulating factor induces activation and restores respiratory burst activity in monocytes from septic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Interleukin-1 administration to C3H/HeJ mice after but not prior to infection increases resistance to Salmonella typhimurium

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Interleukin-1 (IL-1)-induced resistance to bacterial infection: role of the type I IL-1 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Interleukin-12 modulates the protective immune response in SCID mice infected with Histoplasma capsulatum

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Endogenous interleukin-12 regulates acquired resistance in experimental visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Recombinant interleukin 12 cures mice infected with Leishmania major

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Interleukin-12 promotes recovery from viral encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

Interleukin-15 augments superoxide production and microbicidal activity of human monocytes against Candida albicans.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900161-2

7 January 2021

10.1016/S0924-8579(99)00161-2

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10773486